Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

Recursive Superintelligence has raised $650 million at a $4.65 billion valuation in a funding round led by GV and Greycroft, according to the company. The round also included participation from AMD ...

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...

Najat Khan looks at successful platform companies like Vertex, Regeneron and Alnylam and sees a path for Recursion to join them—if the company stays disciplined. (Recursion Pharmaceuticals) Chris ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. logos of OpenAI There’s interesting news coming from Sam Altman’s empire, a firm known for ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

For example, Nvidia owns stakes in six smaller companies. I think Recursion Pharmaceuticals (RXRX +3.86%) is arguably the most intriguing of the group. Recursion looks like a big dud so far. The ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...